Trademark: 90879826
Status Date
Tuesday, December 5, 2023
Filing Date
Thursday, August 12, 2021
5 Biological preparations for gene therapy; adeno-associated virus (AAV) gene therapy preparations and pharmaceuticals; Biological preparations for treatment of neurological diseases and disorders; gene therapy preparations for treatment of disease, namely, neurological diseases; medical preparations and pharmaceuticals for treatment of neurological diseases via gene replacement, gene knockdown, or vectorized antibodies; gene therapy preparations for neurological diseases; nucleic acids encoding polypeptides for gene therapy; Drug delivery agents comprising compounds that facilitate delivery of a wide range of pharmaceuticals and biotherapeutics; Drug delivery agents comprising capsids that facilitate delivery of a wide range of pharmaceuticals and biotherapeutics
44 Medical treatment of neurological diseases via gene replacement, gene knockdown, or vectorized antibodies, namely, Parkinson's disease, Huntington's disease, Friedreich's ataxia, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, tauopathies, synucleinopathies, and neurodegenerative disease
42 Pharmaceutical research and development in the field of gene therapy; Pharmaceutical research and development for the treatment of neurological diseases and disorders; scientific research in the field of gene therapy; pharmaceutical research services; research and development of pharmaceutical preparations for gene therapy; research and development of pharmaceutical preparations for neurological diseases; biotechnology research services; research and development of platform technologies for genetic delivery of therapies and pharmaceuticals; research and development services in the field of platforms technologies for genetic delivery of therapies and pharmaceuticals; research and development in the pharmaceutical and biotechnology fields; research and development regarding the use of RNA-derived functional screening platforms to discover, research and develop novel capsids for genetic deliver of therapies and pharmaceuticals; research and development regarding the identification and targeting of specific cells and tissues for gene therapy delivery
Dec 5, 2023
Report Completed Suspension Check Case Still Suspended
May 19, 2023
Report Completed Suspension Check Case Still Suspended
Nov 14, 2022
Notification Of Letter Of Suspension E-Mailed
Nov 14, 2022
Letter Of Suspension E-Mailed
Nov 14, 2022
Suspension Letter Written
Nov 11, 2022
Teas/Email Correspondence Entered
Nov 10, 2022
Correspondence Received In Law Office
Nov 10, 2022
Teas Response To Office Action Received
May 10, 2022
Notification Of Non-Final Action E-Mailed
May 10, 2022
Non-Final Action E-Mailed
May 10, 2022
Non-Final Action Written
May 7, 2022
Assigned To Examiner
Oct 4, 2021
New Application Office Supplied Data Entered
Aug 16, 2021
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
